Skip to main content


Freshfields advises on YSB Inc.’s IPO on HKSE

Freshfields Bruckhaus Deringer ('Freshfields') has provided Hong Kong and US law advice to the sole sponsor, sole overall coordinator and underwriters in the global offering and listing of shares of YSB Inc. on the Hong Kong Stock Exchange (‘HKSE’). The gross proceeds raised from the global offering are approximately HK$316m before any exercise of the over-allotment option. Trading in the shares commenced today (28 June 2023).

YSB Inc. is China’s largest and fast-growing digital pharmaceutical platform serving businesses outside of hospitals. YSB Inc. recorded a GMV of RMB37.8 billion in 2022, representing a market share of 21.0 per cent in China’s digital market of outside-of-hospital pharmaceutical circulation services. As an enabler of the digitalisation of the outside-of-hospital pharmaceutical and medical service market, YSB Inc. has developed technology-backed solutions to connect and empower the upstream, including pharmaceutical companies, distributors and vendors, and the downstream, including pharmacies and primary healthcare institutions.

The Freshfields team advising on the transaction was led by partner and head of China ECM Richard Wang and partner Howie Farn. They were supported by senior associate Chongming Ma and associates Yuwei Tian, Zedong Liu, Zhuolin Li and Zijian Cao.


Notes to editors

About Freshfields Bruckhaus Deringer

Freshfields Bruckhaus Deringer is a global law firm with a long-standing track record of successfully supporting the world's leading national and multinational corporations, financial institutions and governments on groundbreaking and business-critical mandates. Our 2,800-plus lawyers deliver results worldwide through our own offices and alongside leading local firms. Our commitment, local and multinational expertise, and business know-how means our clients rely on us when it matters most.